11th–12th February 2021


Novartis’ Haematology Masterclass has historically been a two-day face-to-face meeting that aims to support healthcare professionals with a special interest in haematology to share the latest thinking and trial data within the field. By sharing this critical information, the meeting will help to support the implementation of best clinical practice with a focus on the future of patient care within some of the most challenging haematological disorders.

Due to COVID-19 and the current social distancing measures in the UK, Haematology Masterclass 2021 will be hosted virtually. The event will run from 11th–12th February 2021. Please register your interest for the event to receive updates on how the meeting will run and who our guest speakers will be.


Haematology Masterclass has been running for the past six years and continues to deliver the most up-to-date and thought-provoking data in the field of haematology. Since 2014, the meeting has brought presentations from leading specialists in the UK and globally.


Due to Novartis’ dedication to developing life-changing medicines, Haematology Masterclass is able to deliver presentations covering a wide spectrum of conditions. These include:

  • Myeloid proliferative neoplasms (MPN)
  • Immune thrombocytopenia (ITP)
  • Chronic iron overload and haemoglobinopathy
  • Myelodysplastic syndrome (MDS)
  • Acute myeloid leukaemia (AML)
  • Chronic myeloid leukaemia (CML)
  • CAR T-cell therapy

Our promise

Novartis is truly committed to providing world-class education to our UK healthcare professionals. We recognise the value this meeting brings to a vast range of physicians including registrars, nurses, pharmacists and consultants. We hope that you can join us for our next meeting in 2021.

This meeting is funded and organised by Novartis.

ONC20-C098(2) September 2020.

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]